• Reuters

    BioNTech says 90% of 2024 revenues will accrue at end of year

    Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would come in at the end of the year. BioNTech said in a statement that it is still targeting 2024 revenues in a range of 2.5 billion euros ($2.69 billion) to 3.1 billion euros. "BioNTech expects to recognize approximately 90% of its full year revenues in the last months of 2024," the company added.

  • Reuters

    UPDATE 1-Shah Capital urges Novavax shareholders to vote against three directors

    Hedge fund Shah Capital on Monday urged Novavax shareholders to vote against re-election of three directors on the board of the COVID-19 vaccine maker. Shah Capital, which currently owns a nearly 7.5% stake in Novavax, said it intends to vote against directors Richard Douglas, Margaret McGlynn and David Mott at the company's upcoming shareholder meeting in June. "We believe that fresh perspectives are desperately needed in the boardroom to steer Novavax towards sustainable profitable growth," the hedge fund said in a statement.

  • Simply Wall St.

    Interested In Cohen & Steers' (NYSE:CNS) Upcoming US$0.59 Dividend? You Have Three Days Left

    Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...